Trulieve Q2 2026 revenue fell 10% to USD 271 million; gross margin eased 1 percentage point to 60%.
GAAP net loss attributable to common shareholders widened to USD 406 million, or USD 2.10 per share, including a USD 407 million Harvest deconsolidation impact.
Non-GAAP adjusted net income turned to USD 20 million, or USD 0.11 per share; adjusted EBITDA slipped 11% to USD 98 million.
Cash flow from operations dropped to USD 53 million; non-GAAP free cash flow declined to USD 32 million.
Operational update and balance sheet
Listed on the NYSE under TRLV; filed DEA registration applications after Schedule III rescheduling, began Georgia pharmacy shipments, ended Q2 with USD 325 million cash.
TRLV•
